Synthesis of obeticholic acid, a farnesoid X receptor agonist, and its major metabolites labeled with deuterium

被引：2

作者：

Gai, Kuo ^{[1
]}

Huang, Yu ^{[1
]}

Liu, Baomin ^{[1
]}

Zhang, Yinsheng ^{[1
]}

机构：

[1] Chia Tai Tianqing Pharmaceut Grp Co LTD, Jiangsu Key Lab Targeted Antiviral Res, 699-8 Xuanwu Ave,Bldg 9, Nanjing 210023, Jiangsu, Peoples R China

来源：

JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS | 2018年 / 61卷 / 10期

关键词：

deuterium-labeling; internal standards; metabolites; obeticholic acid;

D O I：

10.1002/jlcr.3643

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Simple and facile methods for the synthesis of deuterium-labeled obeticholic acid and its 2 metabolites, glycine and taurine conjugates of obeticholic acid, are described herein. The 3 deuterated compounds were applicable for use as internal standards in drug development.

引用

页码：799 / 804

页数：6

共 50 条

[31] A LONG TERM SAFETY EXTENSION TRIAL OF THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) AND UDCA IN PRIMARY BILIARY CIRRHOSIS (PBC)
Hirschfield, Gideon M.
Mason, Andrew L.
Gordon, Stuart C.
Luketic, Velimir A.
Mayo, Marlyn
Vincent, Catherine
Lindor, Keith D.
Pares, Albert
Kowdley, Kris V.
Trauner, Michael
Esguerra, Maria
Boehm, Olaf
Shapiro, David A.
HEPATOLOGY, 2011, 54 : 429A - 429A
[32] OBETICHOLIC ACID, A FARNESOID-X RECEPTOR AGONIST, REDUCES BACTERIAL TRANSLOCATION AND RESTORES INTESTINAL PERMEABILITY IN A RAT MODEL OF CHOLESTATIC LIVER DISEASE
不详
JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S1 - S2
[33] THE FARNESOID-X-RECEPTOR AGONIST OBETICHOLIC ACID FURTHER INCREASES BILIARY EXCRETION OF ASYMMETRIC DIMETHYLARGININE DURING HEPATIC ISCHEMIA/REPERFUSION INJURY
Di Pasqua, L. G.
Berardo, C.
Rizzo, V.
Adorini, L.
Richelmi, P.
Vairetti, M.
Ferrigno, A.
JOURNAL OF HEPATOLOGY, 2016, 64 : S315 - S315
[34] Progesterone Metabolites as Farnesoid X Receptor Inhibitors
Abu-Hayyeh, Shadi
Williamson, Catherine
DIGESTIVE DISEASES, 2015, 33 (03) : 300 - 306
[35] Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand
Junhui Yu
Kui Yang
Jianbao Zheng
Wei Zhao
Xuejun Sun
Cancer Gene Therapy, 2021, 28 : 590 - 601
[36] Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand
Yu, Junhui
Yang, Kui
Zheng, Jianbao
Zhao, Wei
Sun, Xuejun
CANCER GENE THERAPY, 2021, 28 (06) : 590 - 601
[37] Regulation of Intestinal UDP-Glucuronosyltransferase 1A1 by the Farnesoid X Receptor Agonist Obeticholic Acid Is Controlled by Constitutive Androstane Receptor through Intestinal Maturation
Weber, Andre A.
Mennillo, Elvira
Yang, Xiaojing
van der Schoor, Lori W. E.
Jonker, Johan W.
Chen, Shujuan
Tukey, Robert H.
DRUG METABOLISM AND DISPOSITION, 2021, 49 (01) : 12 - 19
[38] Suppression of Lung Nitrogen Mustard-induced Pulmonary Fibrosis, Oxidative Stress and Inflammatory Macrophage Activation by the Farnesoid X Receptor Agonist, Obeticholic Acid
Meshanni, J.
Sun, R.
Vayas, K.
Guo, G.
Gow, A.
Laskin, J.
Laskin, D. L.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[39] THE SYNTHESIS OF DEUTERIUM LABELED METABOLITES OF WARFARIN AND PHENPROCOUMON
HEIMARK, LD
TOON, S
LOW, LK
SWINNEY, DC
TRAGER, WF
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 1986, 23 (02): : 137 - 148
[40] Correction: Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand
Junhui Yu
Kui Yang
Jianbao Zheng
Wei Zhao
Xuejun Sun
Cancer Gene Therapy, 2022, 29 : 871 - 872

← 1 2 3 4 5 →